ProT2® MHC Class II Tetramers 

used to study tolerance to infused FVIII in hemophilia A mediated by PD-L1+ Tregs

Becker-Gotot J., et al. (2022).  "Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs", J Clin Invest. 132(22):e159925 https://doi.org/10.1172/JCI159925

Abbreviated summary:

A major complication of hemophilia A therapy is the development of alloantibodies (inhibitors) that neutralize intravenously administered coagulation factor VIII (FVIII). Immune tolerance induction therapy (ITI) by repetitive FVIII injection can eradicate inhibitors, and thereby reduce morbidity and treatment costs. It was shown that immune tolerance against FVIII under nonhemophilic conditions was maintained by PD-L1–expressing Tregs that ligated PD-1 on FVIII-specific B cells, causing them to undergo apoptosis. It was shown that PD-1–mediated B cell tolerance against FVIII operated in healthy individuals and in patients with hemophilia A without inhibitors, and that ITI reengaged this mechanism. 

Figure ProT2® MHC Class II Tetramer staining of rhFVIII-treated subjects (see Figure 4 in full publication for details https://doi.org/10.1172/JCI159925

ProT2® MHC Class II Tetramer

Dear Researchers,

ProT2® MHC Class II Tetramers allow you to detect single antigen-specific CD4+ T cells accurately by flow cytometry. They can also be used to separate cells for culture, expansion and further study. ProT2® Tetramers enable you to study in depth CD4+ T cell immune responses in a wide range of disease areas including autoimmune disease, cancer and infectious diseases. ProT2® Tetramers are made by ProImmune’s experienced team who have been providing superior MHC reagents for more than 20 years, including our world-leading Pro5® MHC Class I Pentamers. Custom ProT2® Tetramers are available within approximately 6 weeks from ordering.

Key Publications of ProT2® MHC Class II Tetramers

Hartnell F. et al. (2020). Characterising HCV specific CD4+ T-cells following viral-vectored vaccination, directly acting anti-virals and spontaneous viral cure. https://doi.org/10.1002/hep.31160

Gliwinski M. et al. (2020). Proinsulin-specific T regulatory cell may control immune responses in type 1 diabetes: implications for adoptive therapy. http://dx.doi.org/10.1136/bmjdrc-2019-000873

Cianciotti B. et al. (2019). CD4+ memory stem T cells recognizing citrullinated epitopes are expanded in patients with rheumatoid arthritis and sensitive to tumor necrosis factor blockade. https://doi.org/10.1002/art.41157